USPTO serial 79417917
SAMYANG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 14, 2026
- Examiner
- MANCA, ALBERTO I
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SAMYANG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard Y. Kim
Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for health care, namely, nutritional supplements; vaccines; food supplements; natural remedy preparations for the treatment of hangover with vitamin B1 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin B2 containing yeast-based ingredients for medical purposes; natural remedy preparations for the treatment of hangover with vitamin C containing yeast-based ingredients for medical purposes; vitamin and mineral dietary supplements; veterinary substances and preparations, namely, veterinary vaccines; medicinal preparations for the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; filled syringes for medical purposes containing pharmaceuticals in the nature of anti-infectives; antibiotic ointments for pharmaceutical purposes; cachets for pharmaceutical purposes in the nature of pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations being hormone preparations in the nature of preparations for the suppression of hormones for human use; pills for pharmaceutical purposes for the treatment of cancer and prevention of viruses; pills for pharmaceutical purposes, namely, pills for the treatment of viral, bacterial, and fungal infection and immune disorder; ferments for pharmaceutical purposes; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films and coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of respiratory diseases; pre-filled syringes for medical purposes sold filled with pharmaceuticals for skin care, skin regeneration, skin moisturization, aesthetic treatments, and hyaluronic acids, Botulinum toxin, and pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; pharmaceutical preparations for skin care, namely, skin anti-aging preparations for medical use; pharmaceuticals preparation, namely, pharmaceutical fillers in the nature of injectable dermal fillers, bone fillers consisting of living materials, bone void fillers consisting of natural materials for medical use; pharmaceutical syringes prefilled with medical hyaluronic acid as the main ingredient; medicinal drinks; pharmaceutical drugs, namely, antipyretics, anti-infectives, antineoplastics, diuretics, and pharmaceutical preparations for the treatment of immune system disorders, disorders of the central nervous system, endocrine disorders, gastrointestinal diseases, dermatological diseases, infectious diseases, cardiovascular diseases, and respiratory diseases; medicinal infusions for treating dermatological, kidney, heart, urological, and circulatory diseases, as well as cancer and inflammatory conditions; pharmaceuticals, namely, antivirals; pharmaceuticals, namely, pharmaceuticals for the treatment of cancer; human vaccine preparations; medicines for human purposes for dental purposes; medicines for human purposes for the treatment of cardiovascular and cerebrovascular diseases; medicines for human purposes for the treatment of cancer; medicines for human purposes for the treatment and prevention of iron deficiency and anemia; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for wrinkle treatment; injectable pharmaceutical preparations in the nature of injectable dermal fillers for filling wrinkle in the form of gel; injectable dermal fillers; implantable medicines for the prevention and treatment of diabetes; implantable medicines for the prevention and treatment of cardiovascular diseases; implantable medicines for the prevention and treatment of central nervous system diseases; implantable medicines for the prevention and treatment of cancer; implantable medicines for the prevention and treatment of metabolism diseases; nutraceutical preparations for therapeutic and medical purposes, namely, nutraceuticals for the treatment of cancer, diabetes, and headaches; dermatological pharmaceutical products; gels, creams and solutions for dermatological use; pharmaceutical preparations for use in dermatology, namely, injectable dermal fillers; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin whitening; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin care, namely, injectable pharmaceutical preparations for skin moisturizing; pharmaceutical preparations for skin care; pharmaceutical preparations for skin care, namely, pharmaceutical preparations for skin regeneration; antibiotics; nicotine patches for use as aids to stop smoking; pharmaceutical preparations used in the smoking cessation, namely, smoking cessation preparations; anti-adhesion agents for medical purposes, namely, anti-adhesion gels for use with wound drainage devices; surgical glues; denture adhesives; dental adhesives; medical adhesives for binding internal tissue; medical adhesives for binding wounds; hemostatics for medical purposes; transdermal patches for medical treatment for use in the treatment of psoriasis, acne, fungal infection, and skin disorders; anti-cancer preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks owned by Samyang Holdings Corporation
- Other trademarks in Class 005
- Similar marks named SAMYANG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 23, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 22, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 13, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 26, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 14, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 14, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 14, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 29, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 29, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 29, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 29, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 23, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 2, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 2, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 12, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 21, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Feb 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |